Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: FDA Casts Wide Net For Creation Of User Fees

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency seeks "consultation meetings" with patient, consumer, professional and academic groups as it develops congressionally-mandated report on the nascent approval pathway.

You may also be interested in...



PDUFA V: FDA Offers Mid-Cycle Review Talks, But Industry Wants Them Later

As negotiations about the next user fee cycle continue, FDA is offering an opportunity for sponsors to formally discuss an application's progress with reviewers, although it appears the new proposed meeting would come too early in the process for industry’s satisfaction.

FDA Searches For Clinical Trial Middle Ground At Biosimilar Hearing

FDA appeared to be searching for a way to limit the clinical trial requirements for biosimilars during a two-day public hearing on implementing a pathway for the products.

Generic User Fee Negotiations: Should Different Kinds Of ANDAs Pay More?

The generic industry largely rejects one of the theoretical structures floated by FDA for an ANDA user fee program: paying more for reviews of complex drugs. But the concept does have support from many consumer advocates and at least one member of the Generic Pharmaceutical Association's board of directors, suggesting that the approach might continue to guide regulatory thinking even if it is not part of the final deal between industry and the agency.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel